Predictive and prognostic significance of cytoplasmic expression of ELAV-like protein HuR in invasive breast cancer treated with neoadjuvant chemotherapy

MiR-200c and HuR in ovarian cancer

(2013) Silvia Prislei et al.   BMC CANCER

Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy

(2013) Stefan Glück et al.   BREAST CANCER RESEARCH AND TREATMENT

Multiple Functions of the RNA-Binding Protein HuR in Cancer Progression, Treatment Responses and Prognosis

(2013) Jun Wang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer

(2013) Wijdan Al-Ahmadi et al.   JOURNAL OF PATHOLOGY

High Expression of HuR in Cytoplasm, but Not Nuclei, Is Associated with Malignant Aggressiveness and Prognosis in Bladder Cancer

(2013) Yasuyoshi Miyata et al.   PLoS One

Cytoplasmic expression of the ELAV-like protein HuR as a potential prognostic marker in esophageal squamous cell carcinoma

(2013) Cong Zhang et al.   TUMOR BIOLOGY

Cytoplasmic HuR expression correlates with P-gp, HER-2 positivity, and poor outcome in breast cancer

(2013) Zhongpeng Zhu et al.   TUMOR BIOLOGY

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

(2012) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled Analysis

(2012) Michail Ignatiadis et al.   JOURNAL OF CLINICAL ONCOLOGY

Downregulation of HuR as a new mechanism of doxorubicin resistance in breast cancer cells

(2012) Elisa Latorre et al.   Molecular Cancer

Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers

(2011) Yasuto Naoi et al.   CANCER

The mRNA Stability Factor HuR Inhibits MicroRNA-16 Targeting of COX-2

(2011) L. E. Young et al.   MOLECULAR CANCER RESEARCH

Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells

(2010) Christine Hostetter et al.   CANCER BIOLOGY & THERAPY

HuR Regulates  -Tubulin Isotype Expression in Ovarian Cancer

(2010) G. Raspaglio et al.   CANCER RESEARCH

Overexpression of the RNA binding protein HuR impairs tumor growth in triple negative breast cancer associated with deficient angiogenesis

(2010) Matthew M Gubin et al.   CELL CYCLE

Current and emerging biomarkers in breast cancer: prognosis and prediction

(2010) Marion T Weigel et al.   ENDOCRINE-RELATED CANCER

Cytoplasmic HuR expression correlates with angiogenesis, lymphangiogenesis, and poor outcome in lung cancer

(2010) Jun Wang et al.   MEDICAL ONCOLOGY

pp32 (ANP32A) Expression Inhibits Pancreatic Cancer Cell Growth and Induces Gemcitabine Resistance by Disrupting HuR Binding to mRNAs

(2010) Timothy K. Williams et al.   PLoS One

MicroRNA-125a represses cell growth by targeting HuR in breast cancer

(2010) Xun Guo et al.   RNA Biology

A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy

(2009) Yiing Lin et al.   BREAST CANCER RESEARCH AND TREATMENT

The Role of HuR in Gemcitabine Efficacy in Pancreatic Cancer: HuR Up-regulates the Expression of the Gemcitabine Metabolizing Enzyme Deoxycytidine Kinase

(2009) C. L. Costantino et al.   CANCER RESEARCH

The Expression of RNA-Binding Protein HuR in Non-Small Cell Lung Cancer Correlates with Vascular Endothelial Growth Factor-C Expression and Lymph Node Metastasis

(2009) Jun Wang et al.   ONCOLOGY

HuR and the bioenergetic signature of breast cancer: a low tumor expression of the RNA-binding protein predicts a higher risk of disease recurrence

(2008) Álvaro D. Ortega et al.   CARCINOGENESIS

Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

(2008) Priya Rastogi et al.   JOURNAL OF CLINICAL ONCOLOGY